Patient consent to publication and data sharing in industry and NIH-funded clinical trials
PublisherBioMed Central Ltd.
MetadataShow full item record
AbstractBackground: Participants are recruited into clinical trials under the assumption that the research will contribute to medical knowledge. Therefore, non-publication trials-and, more recently, lack of data sharing-are widely considered to violate the trust of trial participants. Existing practices regarding patient consent to publication and data sharing have not been evaluated. Analyzing informed consent forms (ICFs), we studied what trial participants were told regarding investigators' intention to contribute to medical knowledge, publish trial results, and share de-identified trial data. Methods: We obtained 98 ICFs of industry-funded pre-marketing trials for all (17) antibiotics approved by the European Medicines Agency and 46 ICFs of publicly funded trials from the National Heart, Lung and Blood Institute Biologic Specimen and Data Repository Information Coordinating Center (BioLINCC) data repository. Three authors independently reviewed ICFs to identify and extract what was stated or implied regarding: (1) publication of results; (2) sharing de-identified data; (3) data ownership; (4) confidentiality of identifiable data; and (5) whether the trial will produce knowledge that offers public benefit. Consensus was obtained from the two reviewers with the greatest overall agreement on all five measures. Disagreements were resolved through discussion among all authors. Results: Four (3%) trials indicated a commitment to publish trial results; 140 (97%) did not commit to publishing trial results; six (4%) indicated a commitment to share de-identified data with third party researchers. Commitments to share were more common in publicly funded trials than industry-funded trials (7% vs 3%). A total of 103 (72%) ICFs indicated the trials will or may produce knowledge that offers public benefits, while 131 (91%) ICFs left unstated who "owned" trial data; of those with statements, the sponsor always claimed ownership. Patient confidentiality was guaranteed in 137 (95%) trials. Conclusions: Our results suggest that consent forms rarely disclose investigators' intentions regarding the sharing of de-identified data or publication of trial results. Copyright 2018 The Author(s).
responsible conduct of research
Clinical Trials as Topic
Identifier to cite or link to this itemhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85046412438&doi=10.1186%2fs13063-018-2651-2&partnerID=40&md5=a65326f72651707ffc4185ebc878ce35; http://hdl.handle.net/10713/8947
- The International Committee of Medical Journal Editors trial data sharing requirement and participants' consent.
- Authors: Dal-Ré R
- Issue date: 2016 Dec
- Are investigators' access to trial data and rights to publish restricted and are potential trial participants informed about this? A comparison of trial protocols and informed consent materials.
- Authors: Paludan-Müller AS, Ogden MC, Marquardsen M, Jørgensen KJ, Gøtzsche PC
- Issue date: 2021 Aug 28
- Informed Consent to Study Purpose in Randomized Clinical Trials of Antibiotics, 1991 Through 2011.
- Authors: Doshi P, Hur P, Jones M, Albarmawi H, Jefferson T, Morgan DJ, Spears PA, Powers JH 3rd
- Issue date: 2017 Oct 1
- Protecting patient privacy when sharing patient-level data from clinical trials.
- Authors: Tucker K, Branson J, Dilleen M, Hollis S, Loughlin P, Nixon MJ, Williams Z
- Issue date: 2016 Jul 8
- American Society of Clinical Oncology policy statement: oversight of clinical research.
- Authors: American Society of Clinical Oncology
- Issue date: 2003 Jun 15